9.350USD+1.74%Mkt Cap: 1.58B USDP/E: —Last update: 2026-05-26
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical dev…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.58B USD
Enterprise Value1.14B USD
Revenue (TTM)65.50M USD
Gross Profit66.49M USD
Net Income (TTM)-437.99M USD
Revenue/Share0.4650 USD
Last Price9.350 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees367
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.96
PEG—
EV/EBITDA-2.53
EV/Revenue17.44
P/S23.25
P/B1.65
EPS (TTM)-3.13
EPS (Forward)-2.28
52W Range
4.15569% of range11.66
52W High11.66 USD
52W Low4.155 USD
Profitability
Gross Margin99.96%
Oper. Margin459241.36%
EBITDA Margin0.00%
Profit Margin-658.43%
ROE-57.23%
ROA-43.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-391.78M USD
CapEx (TTM)4.83M USD
FCF Margin-328.16%
FCF Yield-13.57%
Net Debt-380.72M USD
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.13
Current Ratio7.11
Quick Ratio6.52
Book Value/Sh5.487 USD
Cash/Share2.824 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)20.56 USD
Target Range16.00 USD – 30.00 USD
# Analysts9
Ownership
Shares Out.168.65M
Float128.81M
Insiders6.57%
Institutions81.21%
Short Interest
Short Ratio9.0d
Short % Float9.68%
Short % Out.9.56%
Shares Short16.12M
Short (prev mo.)16.84M
Technical
SMA 509.549 (-2.1%)
SMA 2007.045 (+32.7%)
Beta1.70
S&P 52W Chg28.31%
Avg Vol (30d)1.62M
Avg Vol (10d)1.54M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—